RGC
Income statement / Annual
Last year (2025), Regencell Bioscience Holdings Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Regencell Bioscience Holdings Limited's net income was -$3.58 M.
See Regencell Bioscience Holdings Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$392.74 K
|
$745.59 K
|
$769.69 K
|
$604.40 K
|
$26.46 K
|
$9.52 K
|
$0.00
|
| Gross Profit |
-$392.74 K
|
-$745.59 K
|
-$769.69 K
|
-$604.40 K
|
-$26.46 K
|
-$9.52 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$948.29 K
|
$1.07 M
|
$1.58 M
|
$2.51 M
|
$438.32 K
|
$386.23 K
|
$228.22 K
|
| General & Administrative Expenses |
$0.00
|
$3.22 M
|
$4.43 M
|
$5.08 M
|
$941.46 K
|
$311.93 K
|
$159.13 K
|
| Selling & Marketing Expenses |
$0.00
|
$125.43 K
|
$262.66 K
|
$25.28 K
|
$1.58 K
|
$114.21 K
|
$3.64 K
|
| Selling, General & Administrative Expenses |
$2.43 M
|
$2.92 M
|
$4.69 M
|
$5.11 M
|
$943.04 K
|
$426.14 K
|
$162.77 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$3.38 M
|
$3.99 M
|
$6.27 M
|
$7.62 M
|
$1.38 M
|
$812.37 K
|
$390.99 K
|
| Cost And Expenses |
$3.77 M
|
$4.74 M
|
$6.27 M
|
$7.62 M
|
$1.38 M
|
$812.37 K
|
$390.99 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$392.74 K
|
$745.59 K
|
$769.69 K
|
$604.40 K
|
$26.46 K
|
$9.52 K
|
$390.99 K
|
| EBITDA |
-$3.19 M |
-$3.62 M |
-$5.29 M |
-$6.99 M |
-$1.35 M |
-$802.86 K |
-$390.99 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$185.77 K
|
$373.51 K
|
$211.34 K
|
$23.22 K
|
$34.62 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$3.58 M
|
-$4.36 M
|
-$6.06 M
|
-$7.59 M
|
-$1.35 M
|
-$812.37 K
|
-$390.99 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$390.99
|
| Net Income |
-$3.58 M
|
-$4.30 M
|
-$5.87 M
|
-$7.42 M
|
-$1.35 M
|
-$812.37 K
|
-$390.99 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.0072 |
-0.0087 |
-0.0119 |
-0.015 |
-0.0028 |
-0.0017 |
-0.00081267 |
| EPS Diluted |
-0.0072 |
-0.0087 |
-0.0119 |
-0.015 |
-0.0028 |
-0.0017 |
-0.00081267 |
| Weighted Average Shares Out |
$494.49 M
|
$494.49 M
|
$494.49 M
|
$494.49 M
|
$480.40 M
|
$480.40 M
|
$480.40 M
|
| Weighted Average Shares Out Diluted |
$494.49 M
|
$494.49 M
|
$494.49 M
|
$494.49 M
|
$480.40 M
|
$480.40 M
|
$480.40 M
|
| Link |
|
|
|
|
|
|
|
